image credit- shutterstock
Steris Healthcare, a Mumbai-headquartered pharma startup with operations in Navi Mumbai, has announced a Rs 50 crore multi-pronged growth strategy, including a major expansion into South India, a doubling of production capacity, and plans to launch its Initial Public Offering (IPO) in FY 2026-27.
The company, which recently crossed Rs 100 crore in annual sales, aims to solidify its national presence and enhance its ability to deliver innovative, affordable healthcare solutions.
As part of its strategic expansion, Steris Healthcare will establish a state-of-the-art manufacturing facility in South India, targeting key markets in Kerala, Tamil Nadu, Hyderabad (Telangana), and Bengaluru (Karnataka).
This move is designed to streamline supply chains and strengthen the company's reach in high-demand regions. The new plant will double Steris' production capacity by 100%, adding (XX) units to its existing infrastructure, enabling the company to meet growing domestic and international demand while adhering to stringent quality standards.
In addition to scaling operations, Steris Healthcare will launch new medications and healthcare products aimed at addressing critical therapeutic needs. This initiative reflects the company's unwavering commitment to innovation and bridging gaps in medical care. The expansion is also expected to generate 800 new jobs across manufacturing, R&D, sales, and logistics, fostering economic growth in South India.
The proposed IPO, slated for FY 2026-27, will support Steris' growth objectives, including infrastructure development, R&D advancements, and market diversification. The company is collaborating with financial advisors to ensure compliance with regulatory frameworks and to align with investor expectations for a successful public listing.
